Tag Archives: GW Pharmaceuticals

GW Pharmaceuticals Plc. Soared 1,030%, with More Gains to Come

GW Pharmaceuticals Plc. Soared 1,030%, with More Gains to Come

GW Pharmaceuticals Plc. Soared 1,030%, with More Gains to Come

GW Pharmaceuticals Plc. is a biopharmaceutical company that discovers, develops, and commercializes cannabinoid prescription medicines. Since May 10, 2013, the stock price has climbed 1,033%.

The 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors

The 1 Word in GW Pharmaceuticals’ Q3 Update That Disappointed Investors

When GW Pharmaceuticals announced its fiscal third-quarter results on Monday, the company provided plenty of information about its performance during the quarter. However, it wasn’t any of the numbers in the update that caused this decline. Instead, one word caused investors’ disappointment.

Which Cannabis Stock Could Be First to $1 Billion in Annual Sales?

Which Cannabis Stock Could Be First to $1 Billion in Annual Sales?

If there is a “Holy Grail” milestone out there for cannabis stocks, it’s the $1 billion sales mark. The first cannabis company to hit $1 billion in sales will likely validate the industry to Wall Street and investors. But which marijuana stock has the best chance at being first to $1 billion in annual sales?

This New Study Should Encourage Marijuana Stock Investors

This New Study Should Encourage Marijuana Stock Investors

The marijuana industry, and marijuana stock investors for that matter, have been expanding by leaps and bounds over the past two decades. One good way to keep this up is through university-based clinical studies. Studies like these really fan the flame of what might be possible with cannabis-based medicines.

Better Know a Marijuana Stock: Canopy Growth Corp.

Better Know a Marijuana Stock: Canopy Growth Corp.

A major Canadian medical marijuana player, Canopy Growth is a producer and retailer of medical cannabis products and oils in our neighbor to the north. It’s also the only other marijuana stock other than GW Pharmaceuticals to bear a $1 billion valuation.

GWPH Phase 3 Results

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex (cannabidiol) Data Released by the American Academy of Neurology

LONDON, April 18, 2017 /Weed Wire/ – GW Pharmaceuticals noted that the American Academy of Neurology (AAN) issued a press release today announcing positive results from a second Phase 3 study (GWPCARE3) of Epidiolex.

These 5 Marijuana Stocks Lost a Combined $193 Million in 2016

These 5 Marijuana Stocks Lost a Combined $193 Million in 2016

These 5 marijuana stocks lost a combined $193 Million in 2016. Though they’re some of the top performers, they’re also among the companies losing the most money on an annual basis.

5 Drug-Developing Marijuana Stocks You Need to Know

5 Drug-Developing Marijuana Stocks You Need to Know

Medical marijuana remains the safest investment route — if you’re forced to choose one — so here’s a brief rundown of the cannabinoid-based drugs working their way through clinical and preclinical trials.

: 3 Marijuana Stocks to Buy if You're Leery of Buying Marijuana Stocks

3 Stocks to Buy if You’re Leery of Buying Marijuana Stocks

Although marijuana stocks have skyrocketed in the last couple of years, many investors have been understandably leery of jumping on board. Check out why investors might like these three stocks that don’t fit the mold of most marijuana stocks.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Epidiolex® Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Lennox-Gastaut Syndrome

LONDON, March 29, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex®.

How to Profit from the U.S.-U.K. Marijuana “Research Gap”

How to Profit From the U.S. and U.K. Marijuana ‘Research Gap’

Legal marijuana flat-Earthers, like U.S. Attorney General Jeff Sessions, have tried many methods to discredit breakthroughs in medical cannabis, but these efforts at discrediting cannabis stop at the U.S. border.

Mentor Capital

Mentor Capital Acquires $1.0 Million of GW Pharmaceuticals, Plc

SAN DIEGO, Calif., March 3, 2017/Weed Wire/ — Mentor Capital, Inc. (OTCQB: MNTR) announced it has taken a $1.0 million position in the stock of GW Pharmaceuticals, Plc (NASDAQ: GWPH), a United Kingdom based group developing a portfolio of cannabinoid prescription medicines.

Top 5 States for Marijuana Stocks

Top 5 States for Marijuana Stocks

Over the next five years, the U.S. marijuana market could be worth tens of billions of dollars, and according to GreenWave Advisors, LLC, these five states could move the needle most for marijuana companies. Learn just how big the marijuana market may be in California, Washington, Pennsylvania, Colorado, and Michigan in 2021.

Top 3 Most Attractive Investment Subsets Of The Cannabis Industry

Top 3 Most Attractive Investment Subsets of the Cannabis Industry

The cannabis industry is expected to reach $50 billion in size by 2026, according to Cowen & Co., making it one of the fastest growing industries in the world. Investors have taken a growing interest in the industry as legalization has spread across North America. Here are three subsets of the cannabis industry that investors may want to consider for the best risk-adjusted returns.

GWPH Phase 3 Results

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma

LONDON, Feb. 7, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study.

How Big Is the Opportunity for Marijuana Stocks in Florida?

How Big Is the Opportunity for Marijuana Stocks in Florida?

Florida is undeniably behind the curve when it comes to passing pro-pot legislation, but the Sunshine State did make up some ground in November, when voters legalized medical marijuana in the state. How big could the medical marijuana market be in Florida for marijuana stocks?

5 Pot Stocks to Watch Now

5 Pot Stocks to Watch Now

Forward-thinking investors are already plotting seven-figure weed windfalls with the top pot stocks from every ecosystem. You see, there’s more to the marijuana industry than just selling cannabis. There are a lot of ways to profit from legal recreational and medical marijuana sales.

'Cannabis in Parkinson's Disease: Growing Like a Weed!'

‘Cannabis in Parkinson’s Disease: Growing Like a Weed!’

“Cannabis in Parkinson’s Disease: Growing Like a Weed!” was presented at the University of Colorado School of Medicine’s Neurology Grand Rounds on Jan. 18, 2017.

How Big Could the Opportunity Be for Marijuana Stocks in California?

How Big Could the Opportunity Be for Marijuana Stocks in California?

The market for marijuana is exploding as Americans overwhelmingly embrace legalization. Analysts are projecting tens of billions of dollars in future marijuana sales, making this an intriguing market for investors.

4 Best Marijuana Stocks to Play the Green Rush

4 Best Marijuana Stocks to Play the Green Rush

Marijuana sales has the potential to greatly add to government’s treasury as well, and it will be immensely helpful in medical fields. Nowadays, it is also easier for banks for provide services for legal marijuana businesses.

Top Marijuana Stocks to Watch in 2017

Top Marijuana Stocks to Watch in 2017

Sales in the legal marijuana industry are skyrocketing, which is why Money Morning created a list of the top marijuana stocks to watch in 2017. But because marijuana is still illegal under federal law, and many of the marijuana stocks on the market are so volatile, this isn’t a list of recommendations. Rather, it’s a list of marijuana stocks they are watching closely in 2017.

Vitality Biopharma: A Seriously Undervalued Cannabis Stock

Vitality Biopharma: A Seriously Undervalued Cannabis Stock

While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.

4 Stocks You Can Buy to Profit From the Rising Use of MMJ

4 Stocks You Can Buy to Profit From the Rising Use of MMJ

According to a report by the equity research firm Cowen & Co., marijuana will generate $50 billion in revenue by 2026. That’s roughly eight times the estimated revenue this year. GW Pharmaceuticals and Insys Therapeutics are two big companies with an even bigger future.

GWPH Phase 3 Results

GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome

LONDON, Dec. 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced additional positive Epidiolex® (cannabidiol or CBD) Phase 3 data in poster presentations at the 70th Annual Meeting of the American Epilepsy Society.

Cannabis & Parkinson's Disease Study Preps for Launch

Cannabis & Parkinson’s Disease Study Preps for Launch

On Oct. 2, 2016, Maureen Leehey, MD, discussed the potential of cannabis in treating Parkinson’s disease at the 3rd Annual Parkinson’s Disease Symposium at the University of Colorado Movement Disorders Center.

GWPH Riding High: Stock Rises on Clinical Trial's Positive Results

GWPH Riding High: Stock Rising on Clinical Trial’s Positive Results

On Sept. 26, 2016, GW Pharmaceuticals (Nasdaq:GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for its third study in the United States on the efficacy of Epidiolex, its experimental CBD-based drug, in treating seizures associated with Lennox-Gastaut syndrome.


Page 1 of 212
Top